Hyderabad: Bharat Biotech, a city-based vaccine manufacturer, today announced the launch of Typbar-TCV, the world`s first clinically proven typhoid conjugate vaccine for six months old infants and adults.Bharat Biotech CMD Krishna M Ella said the new vaccine brings hope to millions by protecting them against typhoid caused by salmonella typhi, a highly virulent and invasive enteric bacterium.Ella said that this is a fourth generation vaccine against typhoid disease which has been proven to provide long term protection to adults and infants. Typhoid vaccines fall short in two major counts, namely long-term protection and protection of children below two years of age."We hope this vaccine will reach millions of people and help reduce the burden of this devastating disease in infants and children," Ella told reporters at a press conference here, adding that his company had commenced commercial production of Typbar-TCV in pre-filled syringes at its vaccine production facility in Genome Valley.
Cocaine may alter the brain within hours
Skin cell defect contributes to allergy development